The Effect of Bilateral Erector Spina Plane Block on Postoperative Analgesia in Cesarean Section Under SpinalAnaesthesia

Summary

Acute pain after cesarean section (SC) can be variable. Untreated pain can affect patients' life quality. Currently regional nerve blocks are frequently used as a part of multimodal analgesia. Erector spina plane block (ESPB), a recently defined interfacial plane block, provides multisegmental analgesia by spreading to both ventral and dorsal branches of the spinal nerve roots in the cranio-caudal plane with a single injection. The aim of this study is to evaluate the effects of ESPB on postoperative pain, analgesic use and patient satisfaction in patients delivered by CS under spinal anesthesia.

Conditions

• Pain, Postoperative

Interventions

OTHER

Spinal anesthesia + bilateral erector spine plane block

Intraoperative period: Spinal anesthesia was administered with 0.5% bupivacaine and fentanyl 12.5mcg at the level of L4-5 interspace in the sitting position. At the end of the surgery, patients were given a sitting position with the help of 2 people for USG-guided ESPB. The high-frequency linear USG probe was placed in the midline at T12 level, after the spinous process visualized, the transverse process was visualized by moving probe 3-4cm laterally. After confirming the location of the needle tip with 1-2ml hydrodissection, 10 ml bupivacaine + 10 ml salin was applied both right and left sides. Postoperative period: If patients' VAS value \>4, 75mg diclofenac intramuscular was administered. After 30 mins if patients' VAS values \>4, 1000mg paracetamol intravenously was administered.

OTHER

Spinal anesthesia

Intraoperative period: Spinal anesthesia was administered with 0.5% bupivacaine and fentanyl 12.5mcg at the level of L4-5 interspace in the sitting position. Postoperative period: If patients' VAS value \>4, 75mg diclofenac intramuscular was administered. After 30 mins if patients' VAS values \>4, 1000mg paracetamol intravenously was administered.

Sponsors & Collaborators

• Ahmet Onat Bermede

  collaborator UNKNOWN

• Süheyla Karadağ Erkoç

  collaborator UNKNOWN

• Volkan Baytaş

  collaborator UNKNOWN

• Bulut Varlı

  collaborator UNKNOWN

• Hanife Asuman Uysalel

  collaborator UNKNOWN

• Ankara University

  lead OTHER

Principal Investigators

• Bengi Şafak · Ankara University

Study Design

Allocation

RANDOMIZED

Purpose

SUPPORTIVE_CARE

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

45 Years

Sex

FEMALE

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2020-05-01

Primary Completion

2021-06-06

Completion

2022-02-01

Countries

• Turkey (Türkiye)

Study Locations